| UHC Commercial Medical & Drug | Luxturna® (Voretigene Neparvovec-Rzyl) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Maximum Dosage and Frequency – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Mechanical Stretching Devices – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Nerve Graft to Restore Erectile Function During Radical Prostatectomy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Neurophysiologic Testing and Monitoring – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Ocrevus® (Ocrelizumab) and Ocrevus Zunovo® (Ocrelizumab and Hyaluronidase-Ocsq) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Percutaneous Patent Foramen Ovale (PFO) Closure – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Plagiocephaly and Craniosynostosis Treatment – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Prolotherapy and Platelet Rich Plasma Therapies – Commercial and Individual Exchange Medical Policy | 2026-01-01 |